Apyx Medical Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.8M | $48.1M | $52.3M | $44.5M | $48.5M |
| Cost of revenue | $19.8M | $18.7M | $18.6M | $15.4M | $14.9M |
| Gross profit | $33.0M | $29.4M | $33.8M | $29.1M | $33.6M |
| Selling, general & administrative | $15.8M | $18.9M | $22.2M | $20.5M | $18.6M |
| Research and development | $3.4M | $5.1M | $5.4M | $4.5M | $4.3M |
| Operating expenses | $39.5M | $48.2M | $53.7M | $52.7M | $48.0M |
| Operating income | -$6.4M | -$18.8M | -$17.3M | -$23.6M | -$14.4M |
| Interest expense | $5.6M | $5.9M | $2.5M | $15,000 | $10,000 |
| Pretax income | -$10.8M | -$23.3M | -$21.3M | -$22.9M | -$14.8M |
| Income tax expense | $270,000 | $252,000 | -$2.4M | $367,000 | $380,000 |
| Net income | -$11.2M | -$23.5M | -$18.7M | -$23.2M | -$15.2M |
| Balance Sheet | |||||
| Cash and equivalents | $31.7M | $31.7M | $43.7M | $10.2M | $30.9M |
| Current assets | $58.5M | $56.4M | $70.4M | $43.0M | $60.7M |
| Total assets | $66.8M | $64.8M | $79.2M | $51.8M | $68.7M |
| Current liabilities | $11.7M | $10.7M | $12.7M | $11.8M | $13.2M |
| Total liabilities | $52.0M | $50.5M | $52.3M | $14.0M | $14.7M |
| Total debt | — | — | $37.5M | — | — |
| Stockholders' equity | $14.5M | $14.2M | $26.7M | $37.6M | $53.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$8.0M | -$18.0M | -$5.2M | -$20.3M | -$10.4M |
| Depreciation and amortization | $655,000 | $599,000 | $692,000 | $890,000 | $903,000 |
| Stock-based compensation | $2.0M | $4.0M | $5.1M | $6.7M | $5.1M |
| Capital expenditure | $1.1M | $722,000 | $533,000 | $1.0M | $723,000 |
| Free cash flow | -$9.1M | -$18.8M | -$5.8M | -$21.3M | -$11.2M |
Shares outstanding 41.9M · Free float 79.8%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.